CGM accuracy and reliability compared to point of care testing in older inpatients with comorbid type 2 diabetes and cognitive impairment

Busra Donat Ergin, M.Sc.[1], Katharina Mattishent, Ph. D[1,2], Anne-Marie Minihane Ph.D.[1], Richard Holt Ph.D. [3], Helen R. Murphy MD. [1,2], Ketan Dhatariya, Ph.D.[1,2], Michael Hornberger, Ph.D.[3]

Author Affiliations: [1] Norwich Medical School, University of East Anglia, NR4 7TJ, Norwich, United Kingdom**,** [2] Norfolk & Norwich University Hospital, Norwich, United Kingdom, [3] Faculty of Medicine, University of Southampton, Southampton, United Kingdom.

Abstract

Background: Older in-patients have a higher prevalence of diabetes and cognitive impairment. Cognitive impairment can make blood glucose management more challenging, since patients might not remember to measure blood glucose or report symptoms. Investigating the accuracy of continuous glucose monitoring (CGM) compared to usual care will inform clinical interpretations in this vulnerable population.

Aim: To compare CGM derived glucose metrics and point-of-care tests (POCT) in older in-patients with T2DM and cognitive impairment and to investigate CGM accuracy compared to POCT in the hospital settings with the same population.

Methods: Thirty-two older people with comorbid T2DM and cognitive impairment were recruited within a tertiary care hospital in the UK. All participants were naive to CGM and were asked to wear blinded Dexcom G7 sensors for up to 10 days. All participants received usual care in their hospital stay including the use of POCT. Key accuracy metrics comprised the mean absolute relative difference (MARD), median absolute relative difference (median ARD), and Clarke Error Grid (CEG), correlation (R^2) analysis. In addition, the percentage of CGM readings falling within ±20% of reference glucose values when the reference was >5.6 mmol/L, or within ±1.1 mmol/L when the reference was ≤5.6 mmol/L (±20%/1.1 mmol/L) was calculated to assess analytical and clinical accuracy.

Results: Thirty participants completed the study. CGM derived mean glucose for time in range (TIR= 4-10 mmol/mol) was 36.23% (min= 0%, max= 90%), time above range (TAR >= 10 mmol/mol) was 62.87% and time below range (TBR <= 3.9 mmol/mol) was 1.03%. Mean TIR based on available POCT readings was 40.84%, TAR was 57.24% and TBR 1.81%, showing similar readings as CGM derived glucose metrics. Comparison of the two resulted in a MARD of 17.4%, and median ARD of 12.2% and the outcome of ±20%/1.1 mmol/L analysis was 72.3%. CEG analysis revealed that 99.3% of the data points fell within the clinically acceptable zones (Zone A and Zone B), and there was a strong correlation (R^2=0.82) between CGM and POCT. CGM captured more hypoglycaemic readings in our participants.

Conclusion: Our study suggests that CGM and POCT derived glucose metrics are largely similar for in-patients with diabetes and cognitive impairment. CGM remains as a safe and clinically acceptable tool, and able to capture more nocturnal hypoglycaemia compared to POCT in a subgroup of patients. These initial findings show that CGM might be a viable alternative for people with comorbid T2DM and cognitive impairment.

Keywords: Continuous glucose monitoring, Hospitalization, Dementia, Inpatients

Corresponding Author: Michael Hornberger, Clinical Neurosciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.; Email: M.hornberger@soton.ac.uk

Funding: This study is supported by the NIHR Research Capability Funding through the Norfolk and Norwich University Hospitals NHS Foundation Trust and Norfolk Diabetes. Dexcom, Inc (San Diego, California) donated half of the sensor kits to our research.

Acknowledgements: We would like to thank the participants in this study for devoting their time for this research. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department for Health and Social Care.

Conflict-of-Interest Disclosure: None.

Introduction

Type 2 diabetes (T2DM) and dementia are common, progressive long-term conditions associated with ageing that mostly affecting older adults [1], [2], [3]. Compared to individuals without diabetes, those with T2DM are approximately 2 times more likely to develop all-cause dementia, as well as having an earlier onset of dementia [2], [3].

At the same time, people with comorbid T2DM and dementia are highly prevalent in hospital populations [4], [5]. Approximately 25% of patients in acute hospital beds are having dementia, the prevalence of individuals with all-cause dementia and T2DM is estimated at 8.3% [4]. Moreover, the comorbidity is associated with having longer hospital stays than those with either T2DM or dementia [6], and comorbid patients have also higher hospital mortality and readmission rates [7]. This is due to several factors but in particular because people with comorbid T2DM and dementia have higher incidence of dysglycaemia (hypo- and hyperglycaemia) [6]. Asymptomatic hypoglycaemia, particularly, emerges as a significant acute complication of diabetes, especially in people with cognitive impairment [8].

Given the increasing incidence of comorbid dementia and T2DM in elder people, it seems essential to consider better glycaemic management in this vulnerable population with T2DM and cognitive impairment. Retrospective data has shown that glycaemic management is the key preventable factor to reduce acute complications of diabetes, and it may be optimised with the use of continuous glucose monitoring (CGM) systems in older people. CGM is associated with reduced hypoglycaemia risk in inpatients and real-time CGM detects asymptomatic dysglycaemia with its frequent and continuous interstitial glucose measurements [9], [10], [11], [12].

However, evidence on CGM accuracy in hospitalised older adults with comorbid type 2 diabetes and cognitive decline, to our knowledge, does not exist. Previous studies explored clinical accuracy and reliability of different CGM sensors compared to point-of-care testing (POCT) in T1DM or T2DM without cognitive impairment/dementia [12], [13], [14], [15], [16]. Further evidence is needed regarding the clinical accuracy and reliability of next-generation CGM systems, compared with POCT particularly in individuals with comorbid T2DM and cognitive impairment.

The current study rectifies this shortcoming by reporting the clinical accuracy and reliability of CGM compared with POCT in hospitalised older adults with comorbid T2DM and cognitive impairment. The analyses are based on a blinded feasibility study [17] we conducted in this population. Due to the blinded nature, neither participants nor clinician had an insight into the CGM readings, providing a more objective approach towards comparing CGM and POCT in this vulnerable population. We hypothesised that CGM and POCT would largely align, similar to previous findings in T2DM alone, however that CGM might be able to pick up hypoglycaemic changes earlier than POCT due to its continuous measurements.

Methodology

A single-centre, prospective, observational study in older in-patients with T2DM and cognitive impairment on non-intensive care units (non-ICU) at Norfolk and Norwich University Hospital, UK.

Eligible participants were older (≥65 years) individuals with T2DM for at least 6 months and who were in-patients on diabetes management medications (i.e. managed not only by diet/lifestyle). Participants were also required to have an Abbreviated Mini-Mental Test (AMT) score equal or less than 8 (out of 10) and/ or a Mini-Addenbrooke's Cognitive Examination (Mini-ACE) UK Version A score ≤21 (out of 30), indicating cognitive impairment. The AMT is commonly used, brief cognitive screening tool within hospitals in the UK. The Mini-ACE is a cognitive screening tool sensitive to earlier cognitive changes using two cut-offs (25 or 21 out of 30) [18], and has been validated in various settings.

Potential participants were excluded if they did not have mental capacity and/or were on end-of-life care, as confirmed by the clinical care teams. We also excluded people who were current CGM users, were undergoing dialysis treatment and showed evidence of skin irritations on the upper arm or abdomen where the CGM sensor would potentially be fitted. We also excluded people who had other major neurological or psychiatric diseases, such as autism, dyslexia, or learning difficulties.

Data collection took place in Norfolk and Norwich University Hospitals NHS Foundation Trust, UK. CGM device was fitted whilst the consented participants were still in-patients. For further details on the recruitment please consult the methods of our feasibility study [17].

CGM device and POCT comparison

We used the Dexcom G7 real-time CGM (rt-CGM) device which is licensed for use in children and adults and available for consumers to directly purchase. The kits consist of auto applicator kits with sensors with transmitter and receivers to be used in the blind mode. We provided blinded receivers to all participants and clinical staff which were paired with their sensors in advance.

The sensors were applied to the back of the upper arm. Interstitial glucose readings were measured continuously, and data was transmitted from the sensor every 5 minutes. Time in range (TIR) was established, using a range set between 4 mmol/L to 10 mmol/L in the receiver, which was the default setting, and similar to recommendations [19], [20], [21].

Participants wore the CGM sensors for a maximum of 10 days during their hospital stay. At the same time, POCT measurements were taken a minimum of 4 times a day, as per clinical protocols. If a hypoglycaemic episode was noticed via POCT, additional POCT measurements were taken, pending clinical need. For the analysis we matched the POCT readings closest to the CGM readings. Specifically, we paired POCT measurement with CGM according to the nearest measurement of CGM; ±2 minutes. The difference between the number of POCT (n=895) and paired measurements (n=767) is due to filtering data to 2.2-22.2 mmol/L to avoid potential bias of ceiling effect of measurements and lack of CGM measurements to match due to battery run out (n=2), coming off the sensor earlier its due

(n=1), misreading (n=1). Additionally, one paired measurement was excluded due to a clinically implausible discrepancy between readings.

Statistical Analyses

All statistical analyses were conducted using RStudio (R version 4.3.2; R Foundation for Statistical Computing, Vienna, Austria). Descriptive statistics were used to summarise participant characteristics, clinical data and glucose-related metrics. Continuous variables were reported as mean with standard deviation (SD) or median, while categorical variables were summarised using frequencies and percentages.

Agreement between CGM and POCT measurements was assessed using Bland–Altman analysis. For each paired measurement, the mean of CGM and POCT values and their difference (CGM − POCT) were calculated. Glucose values outside the analytical measurement range of the CGM device (<2.2 mmol/L or >22.2 mmol/L) were excluded from accuracy analyses and this range is expressed as 'filtered data' in the results chapter.

Bias was defined as the mean difference, and 95% limits of agreement (reported as upper and lower LoA) were calculated as the bias ±1.96 standard deviations (SD).

To evaluate clinical accuracy, we conducted a Clarke Error Grid (CEG) analysis, classifying paired CGM–POCT values into Zones A–E according to their potential clinical impact. The proportion of measurements within clinically acceptable zones (A and B) was reported. Analytical accuracy was further quantified using the mean absolute relative difference (MARD), median absolute relative difference (median ARD), correlation analysis (R^2) and ±20%/1.1 mmol/L which represents the proportion of CGM values within ±20% of POCT readings >5.6 mmol/L or within ±1.1mmol/L of POCT values ≤5.6 mmol/L, and expressed as a percentage.

Ethics

This study has been reviewed and approved by Health Research Authority (HRA) and Health and Care Research Wales (HCRW) on 23rd August 2024 (IRAS project ID: 344263, REC reference: 24/LO/0441).

Results

Participants

Thirty-two participants were recruited, and we included 30 participants in the analyses. We excluded 2 participants: one due to more than 50% missing CGM readings during the 10-day study period; and the second because they were not taking antidiabetic medication.

The mean age was 78.76 ± 6.71 years, with 18 male (60%) and 12 female (40%) participants. 13 participants (43.3%) were living alone, whilst the remainder were living with a partner, child, grandchildren or in a care home (n=2, 6.6%). All participants were retired. Two thirds were secondary school graduates, with 6 (20%) having a higher education degree (Bachelor's or higher) and 5 (16.6%) did not finish high school.

Table-1: Participant characteristics

Participant characteristics	Mean	Median	Min	Max
Age (years) ± SD	78.7 ± 6.7	78	67	94
BMI (kg/cm^2) ± SD	31.2 ± 10.9	28.3	20.7	74.3
HbA1c (mmol/mol) ± SD	75.1 ± 29.5	67	45	154
Medications (N)	10.5 ± 4.4	11	3	20
Hospitalisations (N) in the last 12 months (excluding the time of recruitment)	0.86 ± 1.5	1	0	8
Length of T2DM (Years)	14.9 ± 6.4	12.5	0.6	38

Twenty-four (80%) participants had at least 4 comorbidities at admission. Only 1 participant (3.3%) had a previous diagnosis of dementia which was Lewy body dementia.

Nine (30%) participants were admitted to the hospital due to diabetes (DKA, hypoglycemia, HHS), whilst 1 participant (3.3%) was at hospital due to cognitive impairment and confusion. Ten (33.3%) participants were at hospital due to fall accompanying both diabetes and cognition related reasons.

At the follow up assessment, sixteen participants (53.3%) were still inpatients, including two (6.6%) at different hospitals for rehabilitation. Two participants (6.6%) were discharged to care home or nursing home, while all other fourteen participants (46.6%) were at home by the time we scheduled our visit.

Medications

Most of the participants were treated with insulin; solely or combined therapy, while 43.4% were only on oral glucose anti-diabetes agents, and 33.3% of the participants were using both insulin and oral agents (Table-2). Due to diabetic foot or foot ulcers, 56.6% were regularly using topical agents. Supplements and multivitamins (mostly vitamin D, folic acid and thiamine) were commonly used (73.3%).

Table-2: Medication classes

Anti-Diabetic Medications*	Total Number of participants N (%)
Insulin (solely)	7 (23.3%)
Insulin& oral antidiabetics	10 (33.3%)
Metformin	16 (53.3%)
SGLT-2 inhibitors **DPP4 inhibitors**	9 (30%) 4 (13.3%)
Sulphonylurea	3 (10%)
GLP-1 receptor agonists	1 (3.3%)
Commonly prescribed other medications*	
Statins	20 (66.6%)
Anticoagulants/Antiplatelets	20 (66.6%)
Topical agents	17 (56.6%)
Analgesics	15 (50%)
Antihypertensives**	15 (50%)
Gastric acid suppressive therapy* **Antibiotics**	11 (39%) 8 (26.6%)

**There was overlap between the groups; for example, some metformin users were also prescribed DPP4 inhibitors, and some inpatients receiving statins were also taking anticoagulants.*
*** Antihypertensives include any ACE inhibitors/ARBs, beta blockers, calcium channel blockers, thiazide diuretics and alpha blockers.*
****Acid suppressive therapy defines proton pump inhibitors and H2 receptor antagonists.*

CGM and POCT: TIR, TAR, TBR

CGM-derived mean glucose for time in range (TIR= 4-10 mmol/L) was 36.2% (min= 0%, max= 90%), time above range (TAR ≥ 10 mmol/L) was 62.7% and time below range (TBR ≤ 3.9 mmol/L) was 1.03%. Fourteen (46.6%) participants wore their CGM continuously in hospital, with CGM active for 89.9% of the time (range 86% - 95%).

Overall, CGM data was very similar and consistent to POCT glucose measurements (p=0.97) (Table-2). However, there were individual differences between CGM and POCT, with some individuals showing no TBR (0%) via POCT, whilst CGM observed results 3% and 8% TBR within the same participants.

Table 2: CGM and POCT metrics

Metrics	Mean		Min		Max	
	CGM	**POCT**	**CGM**	**POCT**	**CGM**	**POCT**
Measurements/ day (N)	285	4.8	260	2.5	288	9
Glucose (mmol/L)	12.5	12.4	<2.2*	2.1	>22.2**	>33.3**
CV (%)	39.7	62.7	15.5	14.5	47.4	57.8
SD	5.0	7.8	1.8	1.6	6.1	8.3
TIR (%)	36.2	40.8	0	0	90	92.5
TAR (%)	62.8	57.2	8	3.5	100	100
TBR (%)	1	1.8	0	0	9	12.8

** Lower measurement limit of CGM.*
*** Upper measurement limits of CGM and POCT.*
**** One participant (3.3%) had an apparent CGM sensor fault at day 6 after sensor fitting, leading to consistent above range readings compared to POCT. For this participant, we only included CGM data up to day 6.*

CGM and POCT: MARD, Bias, Clinical Risk Assessment

Matched CGM readings and POCT reference values was evaluated using a filtered scatter plot (n=767) (Figure 1). We summarised the total number of CGM and POCT readings and available time-matched CGM and POCT readings used for accuracy analyses in Figure 2 (Appendix). The results demonstrated a strong correlation (R^2=0.82), although a systematic mean bias of 0.88 mmol/L was observed, indicating a slight overestimation by the CGM sensor. The overall MARD was calculated as 17.43% which represents an acceptable level of numerical accuracy for this device category. Analyses showed 72.32% agreement within ±20%/1.1 mmol/L. We presented other metrics indicating CGM accuracy and reliability in Table 3.

Table 3: Summary of CGM accuracy and reliability metrics

Metrics	**Filtered Data (2.2-22.2 mmol/L)**
MARD (%)	17.43
Median ARD (%)	12.24
R^2 (Correlation)	0.82
±20%/1.1 mmol/L (%)	72.32
Mean bias ±SD	0.88 mmol/L ±2.15
Upper Limit of Agreement (95%)	+5.09 mmol/L
Lower Limit of Agreement (95%)	-3.33 mmol/L

CEG analysis revealed that 99.3% of the data points fell within the clinically acceptable zones (Zone A: 83.1% and Zone B: 16.2%) (Figure 1). These findings confirm the clinical safety of the device, as the vast majority of glucose readings would lead to correct or benign treatment decisions.

i)



ii)



Figure 1. Clinical risk assessment of CGM with CEG and Bland-Altman Analysis

i) Scatter plot diagram showing clinical accuracy of blood glucose levels measured by CGM according to POCT reference values within the filtered range (2.2 – 22.2 mmol/L).

ii) Scatter plot diagram demonstrating bias (0.88), lower LoA (-3.33 mmol) and upper LoA (+5.09 mmol/l) of CGM compared to POCT as the reference.

Hypoglycaemia

Nine participants (30%) experienced hypoglycaemia during the study, according to CGM-derived glucose metrics (≤ 3.9mmol/L). While four (44.4%) out of nine participants experienced only one hypoglycaemic CGM event, others had multiple hypoglycaemic CGM events (mean=3.1, max=8, min=1).

One participant was discharged at the time they experienced hypoglycaemia; therefore, POCT-derived glucose measurements could not be compared to their CGM readings. For the remaining participants who had CGM-derived hypoglycaemic event (n=8), we assessed the rate of captured hypoglycaemia events at hospital via POCT checks. In total, there were 17 missed POCT hypoglycaemic events (62.9%) out of 27 total events, that were captured in those 8 participants by CGM but not POCT (Table-5). Except one measurement (ID20, event 4), all other POCT hypoglycaemic events were captured with a delay of at least 34 minutes up to 4 hours later (ID20, event 5) after CGM showed the first low reading. All participants experiencing hypoglycaemia (n=8) had level 2 hypoglycaemic readings (< 3.0 mmol/L), with only one having a level 1 hypoglycaemic event. Table-6 (Appendix) shows more details in mean glucose per hypoglycaemic event, time spent at hypoglycaemia and if captured by POCT, time gap between first reading of CGM and POCT measurements per participant.

Table- 5: Hypoglycaemic Events by CGM and POCT Capture Rate

Participants	Number of events by CGM	Events missed by POCT N (%)
ID02	1	1 (100%)
ID03	7	4 (57.1%)
ID13	4	2 (50%)
ID14	1	1 (100%)
ID20	8	4 (50%)
ID21	1	0 (0%)
ID24*	1	N/A
ID31	3	3 (100%)
ID32	2	2 (100%)
Total	**27**	**17 (62.9%)**

*ID24 was discharged by the time they experienced hypoglycaemia. We excluded them from analysis.

Discussion

As hypothesised, our findings show that CGM is a safe and reliable tool for older T2DM inpatients with cognitive impairment and captures more hypoglycaemic readings compared to POCT. CGM might allow therefore to complement existing POCT measurements, which are still required to check abnormal readings in in critically ill inpatients [22], and to support clinical decision making [22], [23]. Still, to our knowledge, this is the first non-intensive care unit (non-ICU) hospital setting study in this comorbid population investigating the accuracy of real time CGM.

In more detail, our results show high consistency and no significant group difference between CGM-derived glucose metrics and POCT. However, there were individual differences between CGM and POCT, with some participants showing no TBR via POCT, whilst CGM observed 3-8% TBR within the same participants. Due to the difference between the number of measurements per day, it is expected for real time CGM to capture more dysglycaemic events than intermittent checks by POCT (average 4.8 times/day in our study). Our results are similar to previous hospital setting studies [14], although other studies better TIR via CGM measurements compared to POCT without significant difference in TBR [12], [24],. The reason for this discrepancy may be due to previous studies including a mixture of T1DM and T2DM patients across different age groups, while we focused on older people with T2DM and cognitive impairment specifically. We also used a newer generation CGM sensor with better reported MARD results (Dexcom G7, 8.2%) than previous sensors (12.3% for Abbott Freestyle libre pro, 9.6% for Medtronic Guardian sensor 3) [11], [25]. Together, our TIR, TAR and TBR findings show that CGM and POCT have similar readings in T2DM and cognitive impairment compared to previous studies in related populations.

In terms of accuracy, using blinded sensors without real-time calibrations and adjustments, we found a MARD of 17.4%, with 99.3% of values falling zones A and B in CEG analysis. Most CGM accuracy studies had slightly lower MARD, which were between 11.6%-17.1% [10], [12], [16], [26], [27], [28], [29]. As mentioned above, this difference might be due to wider diabetes and age populations being measured. Further, older sensor generations and inclusion of people with significant renal dysfunction, which we excluded, might explain the discrepancy. Further, some previous studies did not conduct care-as-usual for their POCT measurements but had often a higher frequency, every 5 or 15 minutes, instead of the usual 4 times a day POCT measurements. Still, another study using a mix of T1DM and T2DM patients reported a MARD of 19.2%, and t±20%/1.1 mmol/L of 59.5% which is relatively lower than our results (72.3%) [15].There clearly needs to be further investigation as to how the admixture of T1DM and T2DM as well as different age groups affects potentially CGM and POCT differences. Despite the MARD differences and potential population differences, our CEG results are highly similar to previous studies, which ranged between 96.5%-99% [10], [12], [15], [28]. Interestingly, a previous study also reported that CGM accuracy was lower within hospital settings compared to CGM used in the community, suggesting that daily calibration might be needed within the hospital to improve the accuracy results [15]. Since our study was conducted blinded, calibration was only conducted at the beginning of the study but still produced high CEG results [11], [30]. Overall, CEG analysis and ±20%/1.1 mmol/ results of our study prove that the device remains a safe tool for monitoring in hospital setting, however it should be checked by POCT when patients show any low readings [12], [13], [24], [30].

In terms of hypoglycaemic events, it was surprising that the majority of hypoglycaemic readings (62.9%) in our participants were missed by POCT during their stay. Some of the hypoglycaemic readings via CGM were clearly very brief or occurred during sleep. Still, there was a significant proportion of hypoglycaemic events which were prolonged and during daytime. This is not trivial, since inpatient hypoglycaemia has been associated with adverse outcomes such as prolonged length of stay, higher hospital charges and increased risk for readmission and higher mortality rates [30]. The consensus of clinical targets for CGM suggests for older people is that they should spend less than 15 minutes per day in the hypoglycaemia range; and having TBR <1% for those older and at high risk [31]. Only 11.1% of all episodes lasted less than 15 minutes in our population, and only one participant among those experienced hypoglycaemia met this guideline. Indeed, one third of our participants experienced level 1 hypoglycaemia, and many experienced level 2 hypoglycaemia which require more vigilance and potential clinical interventions in this vulnerable population.

Similarly, our findings suggest that CGM can detect earlier and more hypoglycaemic events, particularly nocturnal and prolonged hypoglycaemia [12], [13], [14], [24]. CGM, therefore, emerges as a significant tool detecting more dysglycaemia in-hospital vulnerable populations with comorbid diabetes and cognitive impairment, compared to POCT. This also chimes with previous RCTs showing improved glycaemic control and significant reduction of hypoglycaemia with CGM in non-ICU hospitalised individuals requiring insulin therapy, compared to POCT alone [32], [33]. Given the increased hypoglycaemia risk, particularly high prevalence of nocturnal hypoglycaemia and its significant consequences among older people with cognitive decline, future use of CGM within this population and setting should be encouraged.

Despite our novel findings in this vulnerable populations, there are still a few shortcomings of our results. First, we conducted this observational study in a relatively small sample within only one hospital. Future research is, therefore need to replicate the findings in a larger sample and across different settings and diverse population. Furthermore, due to the nature of our research setting, participants were admitted for varying acute conditions including emergencies, which might have influenced both cognitive performance and glycaemic outcomes. We made sure that we limited some of those aspects by excluding certain health conditions and also only recruited participants with capacity to consent, ruling out delirium-associated emergency admissions. In addition to those limitations, it is important to acknowledge that directly comparing infrequent POCT results with high frequency CGM data is challenging, as the continuous nature of CGM provides a much denser dataset than occasional finger-prick tests. Some guidelines recommend assessing the accuracy of CGM by comparing to high precision lab instruments as a gold-standard reference [26], [31], [34], [35]. However, such high precision measurements were not available for our research since we conducted an observational study without changing our participants' usual hospital care. Still, our results are valid, they replicate previous studies and also allow more of a real-world evaluation of CGM vs POCT use within the hospital, yet future validation is clearly needed.

In conclusion, our findings confirm CGM as a safe and reliable monitoring tool for older inpatients with T2DM and cognitive impairment and captures more hypoglycaemic readings than in usual care. Nevertheless, dysglycaemic readings should always be verified via POCT before clinical intervention. Future research with larger cohorts and diverse settings is essential to further optimise glucose management protocols for this vulnerable population.

Funding

This study is supported by the NIHR Research Capability Funding through the Norfolk and Norwich University Hospitals NHS Foundation Trust and Norfolk Diabetes. Dexcom, Inc (San Diego, California) donated half of the sensor kits to our research.

Acknowledgements

We would like to thank the participants in this study for devoting their time for this research. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department for Health and Social Care.

References

[1] S. Bellary, I. Kyrou, J. E. Brown, and C. J. Bailey, “Type 2 diabetes mellitus in older adults: clinical considerations and management,” *Nat Rev Endocrinol*, 2021.

[2] D. D.□; Singh *et al.*, “Development of Dementia in Type 2 Diabetes Patients: Mechanisms of Insulin Resistance and Antidiabetic Drug Development,” *Cells*, vol. 11, no. 23, p. 3767, Dec. 2022, doi: 10.3390/CELLS11233767.

[3] L. J. Launer *et al.*, “Rates and risk factors for dementia and Alzheimer’s disease,” *Neurology*, vol. 52, no. 1, pp. 78–78, Jan. 1999, doi: 10.1212/WNL.52.1.78.

[4] B. Gómez-Martín *et al.*, “Prevalence of Dementia among Patients Hospitalized with Type 2 Diabetes Mellitus in Spain, 2011-2020: Sex-Related Disparities and Impact of the COVID-19 Pandemic,” 2023, doi: 10.3390/ijerph20064923.

[5] D. J. Magliano, E. J. Boyko, and I. D. A. 10th edition scientific committee, “IDF DIABETES ATLAS,” *IDF DIABETES ATLAS [Internet]. Brussels*, pp. 1–141, 2021, Accessed: Feb. 27, 2026. [Online]. Available: https://www.ncbi.nlm.nih.gov/books/NBK581934/

[6] D. M. Robinson, D. Regos-Stewart, M. A. Reyes, T. Kuo, and N. C. Barragan, “Comorbidity of Type 2 Diabetes and Dementia among Hospitalized Patients in Los Angeles County: Hospitalization Outcomes and Costs, 2019–2021,” *Diabetology*, vol. 4, no. 4, pp. 586–599, Dec. 2023, doi: 10.3390/DIABETOLOGY4040052/S1.

[7] K. Gadsby-Davis, N. Garner, B. D. Ergin, K. Dhatariya, and M. Hornberger, “The Impact of Comorbid Dementia and Diabetes Mellitus on Hospital Patients’ Outcomes: A Systematic Review and Meta-analysis,” *Diabetes Ther.*, vol. 16, no. 1, pp. 103–120, Jan. 2025, doi: 10.1007/S13300-024-01672-W.

[8] K. Mattishent *et al.*, “Continuous glucose monitoring in older people with diabetes and memory problems: A mixed-methods feasibility study in the UK,” *BMJ Open*, vol. 9, no. 11, Nov. 2019, doi: 10.1136/bmjopen-2019-032037.

[9] S. El-Abd and R. Poole, “The accuracy of capillary blood glucose testing versus real time and intermittently scanned continuous glucose monitoring,” *Practical Diabetes*, vol. 40, no. 5, pp. 40–43a, Sep. 2023, doi: 10.1002/PDI.2479.

[10] Q. ul ain Aziz *et al.*, “Clinical Accuracy of Continuous Glucose Monitoring Immediately After Kidney Transplant in Patients With Type 2 Diabetes,” *Endocr. Pract.*, vol. 31, no. 7, pp. 858–866, Jul. 2025, doi: 10.1016/J.EPRAC.2025.04.022.

[11] M. P. Christiansen *et al.*, “Accuracy of a Fourth-Generation Subcutaneous Continuous Glucose Sensor,” *Diabetes Technol. Ther.*, vol. 19, no. 8, pp. 446–456, Aug. 2017, doi: 10.1089/DIA.2017.0087.

[12] R. J. Galindo *et al.*, “Comparison of the FreeStyle Libre Pro Flash Continuous Glucose Monitoring (CGM) System and Point-of-Care Capillary Glucose Testing in Hospitalized Patients With Type 2 Diabetes Treated With Basal-Bolus Insulin Regimen,” *Diabetes Care*, vol. 43, no. 11, pp. 2730–2735, Nov. 2020, doi: 10.2337/DC19-2073.

[13] M. P. Ukpe and A. C. Ezeanuka, “Assessment of accuracy, clinical validity, and analytical linearity in point-of-care glucose monitoring devices for diabetes mellitus: A systematic review and meta-analysis,” *Clin. Biochem.*, vol. 137, p. 110911, Jun. 2025, doi: 10.1016/J.CLINBIOCHEM.2025.110911.

[14] E. K. Spanakis *et al.*, “Continuous Glucose Monitoring–Guided Insulin Administration in Hospitalized Patients With Diabetes: A Randomized Clinical Trial,” *Diabetes Care*, vol. 45, no. 10, pp. 2369–2375, Oct. 2022, doi: 10.2337/DC22-0716.

[15] M. Y. O'Connor *et al.*, "Accuracy of continuous glucose monitoring in the hospital setting: an observational study," *Diabetologia*, vol. 67, no. 12, pp. 2650–2659, Dec. 2024, doi: 10.1007/S00125-024-06250-0.

[16] Y. M. Luijf *et al.*, "Accuracy and Reliability of Continuous Glucose Monitoring Systems: A Head-to-Head Comparison on behalf of the AP@home consortium", doi: 10.1089/dia.2013.0049.

[17] B. D. Ergin *et al.*, "Continuous Glucose Monitoring in Older In-patients with Type 2 Diabetes and Cognitive Impairment – An open single-arm feasibility study," *medRxiv*, p. 2026.01.26.26344013, Feb. 2026, doi: 10.64898/2026.01.26.26344013.

[18] S. Hsieh *et al.*, "The mini-addenbrooke's cognitive examination: A new assessment tool for dementia," *Dement. Geriatr. Cogn. Disord.*, vol. 39, pp. 1–11, Feb. 2015, doi: 10.1159/000366040.

[19] T. Battelino *et al.*, "Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range," *Diabetes Care*, vol. 42, no. 8, pp. 1593–1603, Aug. 2019, doi: 10.2337/DCI19-0028.

[20] T. Danne *et al.*, "International consensus on use of continuous glucose monitoring," *Diabetes Care*, vol. 40, no. 12, pp. 1631–1640, Dec. 2017, doi: 10.2337/DC17-1600/-/DC1.

[21] E. G. Wilmot *et al.*, "Time in range: A best practice guide for UK diabetes healthcare professionals in the context of the COVID□19 global pandemic," *Diabetic Medicine*, vol. 38, no. 1, p. e14433, Jan. 2020, doi: 10.1111/DME.14433.

[22] P. Avari *et al.*, "Continuous Glucose Monitoring Within Hospital: A Scoping Review and Summary of Guidelines From the Joint British Diabetes Societies for Inpatient Care," *J. Diabetes Sci. Technol.*, vol. 17, no. 3, pp. 611–624, May 2023, doi: 10.1177/19322968221137338.

[23] G. Cavalcante Lima Chagas *et al.*, "Use of continuous glucose monitoring and point-of-care glucose testing in hospitalized patients with diabetes mellitus in non-intensive care unit settings: A systematic review and meta-analysis of randomized controlled trials," Feb. 01, 2025, *Elsevier Ireland Ltd*. doi: 10.1016/j.diabres.2024.111986.

[24] Y. Wang *et al.*, "Real-time continuous glucose monitoring-guided glucose management in inpatients with diabetes receiving short-term continuous subcutaneous insulin infusion: a randomized clinical trial," *Lancet Reg. Health West. Pac.*, vol. 48, p. 101067, Jul. 2024, doi: 10.1016/J.LANWPC.2024.101067.

[25] "CGM l Freesytle Libre pro Features l danatech." Accessed: Mar. 03, 2026. [Online]. Available: https://www.adces.org/education/danatech/glucose-monitoring/continuous-glucose-monitors-(cgm)/view-compare-cgms/product-detail/freestyle-libre-pro

[26] I. I. K. Steineck, Z. Mahmoudi, A. Ranjan, S. Schmidt, J. B. Jørgensen, and K. Nørgaard, "Comparison of Continuous Glucose Monitoring Accuracy between Abdominal and Upper Arm Insertion Sites," *Diabetes Technol. Ther.*, vol. 21, no. 5, pp. 295–302, May 2019, doi: 10.1089/DIA.2019.0014/FORMAT/EPUB.

[27] C. G. Nielsen *et al.*, "Accuracy of continuous glucose monitoring systems in intensive care unit patients: a scoping review," Dec. 01, 2024, *Springer Science and Business Media Deutschland GmbH*. doi: 10.1007/s00134-024-07663-6.

[28] E. Finn, L. Schlichting, L. Grau, I. S. Douglas, and R. I. Pereira, "Real-world Accuracy of CGM in Inpatient Critical and Noncritical Care Settings at a Safety-Net Hospital," *Diabetes Care*, vol. 46, no. 10, pp. 1825–1830, Oct. 2023, doi: 10.2337/dc23-0089.

[29] J. Hohendorff *et al.*, “Accuracy of Dexcom One+ in Patients with Diabetes or Stress Hyperglycemia Hospitalized in Cardiac Intensive Care Unit,” *Diabetes Technol. Ther.*, Jan. 2026, doi: 10.1177/15209156251407717.

[30] E. K. Spanakis *et al.*, “A Consensus Statement for Continuous Glucose Monitoring Metrics for Inpatient Clinical Trials,” *J. Diabetes Sci. Technol.*, vol. 17, no. 6, pp. 1527–1552, 2023, doi: 10.1177/19322968231191104.

[31] “Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range,” 2019, doi: 10.2337/dci19-0028.

[32] G. Cavalcante Lima Chagas *et al.*, “Use of continuous glucose monitoring and point-of-care glucose testing in hospitalized patients with diabetes mellitus in non-intensive care unit settings: A systematic review and meta-analysis of randomized controlled trials,” Feb. 01, 2025, *Elsevier Ireland Ltd*. doi: 10.1016/j.diabres.2024.111986.

[33] L. G. Singh *et al.*, “Reducing Inpatient Hypoglycemia in the General Wards Using Real-time Continuous Glucose Monitoring: The Glucose Telemetry System, a Randomized Clinical Trial,” *Diabetes Care*, vol. 43, no. 11, pp. 2736–2743, Nov. 2020, doi: 10.2337/DC20-0840.

[34] G. Cappon, M. Vettoretti, G. Sparacino, and A. Facchinetti, “Continuous Glucose Monitoring Sensors for Diabetes Management: A Review of Technologies and Applications,” *Diabetes Metab. J.*, vol. 43, no. 4, p. 383, Aug. 2019, doi: 10.4093/DMJ.2019.0121.

[35] J. Han, J. H. Nichols, M. Rice, and D. C. Klonoff, “The End of the Road for the YSI 2300 Analyzer: Where Do We Go Now?,” *J. Diabetes Sci. Technol.*, vol. 14, no. 3, p. 595, May 2019, doi: 10.1177/1932296819886603.

[36] T. Danne *et al.*, “International consensus on use of continuous glucose monitoring,” *Diabetes Care*, vol. 40, no. 12, pp. 1631–1640, Dec. 2017, doi: 10.2337/DC17-1600/-/DC1.

Appendix

Table-6: Time Spent in Hypoglycaemia and Time-of-Day Distribution of CGM Events and POCT Capture

Participants	The number of hypoglycaemic events	Mean glucose (mmol/L)	Min glucose (mmol/L)	Max glucose (mmol/L)	Time spent in hypoglycaemia to CGM (~minutes)	Captured by POCT	If captured, time gap between CGM and POCT (~minutes after)	Nocturnal (12am - 6am)
ID02	1	3.6*	3.2	4	115	No	N/A	Yes
ID03	1	3.6	3.6	3.8	50	Yes	41	No
	2	3.4	3.3	3.8	75	Yes	111	No
	3	3.2	2.8	3.8	70	No	N/A	No
	4	3.6	3.4	3.9	30	Yes	34	No
	5	3.3*,**	2.2	4.4	130	No	N/A	No
	6	3.2*	2.7	4.3	50	No	N/A	No
	7	3.3*	2.2	4.4	105	No	N/A	No
ID13	1	3.9*	3.8	4.1	40	No	N/A	Yes
	2	2.9**	2.2	3.9	105	Yes	45	No
	3	3.8*	3.5	4.5	95	No	N/A	No
	4	3.4*	2.7	5.4	85	Yes	61	No
ID14	1	3.4	2.8	3.9	15	No	N/A	No
ID20	1	3.6	3.5	3.8	130	No	N/A	Yes
	2	3.0	2.6	3.6	245	No	N/A	Yes
	3	3.5	3.2	3.8	130	Yes	85	No
	4	3.8	3.8	3.8	5***	Yes	8 (before****)	No
	5	3.2	2.7	3.8	285	Yes	267	Yes
	6	3.3	2.8	3.8	290	No	N/A	Yes
	7	3.8	3.8	3.8	10***	No	N/A	Yes
	8	3.5	3.2	3.8	65	Yes	40	No
ID21	1	3.8*	3.5	4.2	85	Yes	72	Yes
ID24*****	1	3.0**	2.2	3.9	10***	N/A	N/A	No
ID31	1	3.4*	2.4	4.8	205	No	N/A	No
	2	3.3	3.4	3.9	40	No	N/A	No
	3	2.7*,**	2.2	4.1	230	No	N/A	Yes

ID32	1	2.9*,**	2.2	4.1	525	No	N/A	Yes
	2	2.6**	2.2	3.8	520	No	N/A	Yes
Total	**28**	**3.4**			**≈149 (all) ≈74.7 (diurnal)**	**Captured=10, Missed=17 Nocturnal missed=9**	**≈84 (all) ≈59.5 (diurnal)**	**Yes=11, No=17**

**Participant had >3.9mmol/L readings during hypoglycaemic event, however, did not exceed 20 minutes (2 readings) according to CGM.*

***Participant had <2.2mmol/L readings which are lower cut off CGM. We included them into our statistics as 2.2mmol/L to have valid data.*

****These hypoglycaemic results may not be defined as hypoglycaemic events due to uncertainty of time spent at hypoglycaemia. Events are required to last at least 15 minutes [36]. Therefore, we excluded these three results from the average value (≈149).*

*****Participant's (ID20) 4th hypoglycaemic event was captured 8 minutes before CGM showed low reading. Except this event, other events were captured after CGM showed low glucose results.*

******We only included low readings if POCT is available for the event to match CGM results. ID24 did not have hospital POCT records the time they experienced hypoglycaemia.*

Figure 2. Summary of time-matched CGM and POCT readings used for accuracy analyses



Figure 2. Figure showing the number of CGM and POCT measurements and paired values according to the nearest measurement of CGM; ±2 minutes. The difference between the number of POCT and paired measurements is due to 1. filtering data to 2.2-22.2 mmol/L to avoid potential bias of ceiling effect of measurements 2. lack of CGM measurements to match.